中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

IgG4相关肝胆胰疾病诊疗进展

王天琪 刘燕鹰

引用本文:
Citation:

IgG4相关肝胆胰疾病诊疗进展

DOI: 10.3969/j.issn.1001-5256.2022.04.006
基金项目: 

首都卫生发展科研专项 (2022-2-2026)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:王天琪负责文献检索、撰写文章;刘燕鹰负责文章的整体指导、审核及修改完善。
详细信息
    通信作者:

    刘燕鹰,57495011@qq.com

Advances in diagnosis and treatment of IgG4-related hepatobiliary and pancreatic diseases

Research funding: 

Capital's Fund for Healthy Improvement and Researth (2022-2-2026)

More Information
    Corresponding author: LIU Yanying, 57495011@qq.com(ORCID: 0000-0003-2609-4052)
  • 摘要: IgG4相关肝胆胰疾病是IgG4相关疾病多器官纤维化炎性疾病的一部分,包括IgG4相关自身免疫性胰腺炎、IgG4相关硬化性胆管炎、IgG4相关肝脏病变。主要病理表现为IgG4+浆细胞、淋巴细胞浸润,伴有席纹状纤维化、闭塞性静脉炎和嗜酸性粒细胞浸润。临床诊断多采用IgG4相关疾病综合诊断标准和专科制定的特异性器官受累诊断标准,难点在于与肿瘤性疾病的鉴别,新型诊断标志物有望提高诊断敏感度及特异度。迄今,一线治疗药物仍为糖皮质激素,生物制剂,尤其是CD20单抗疗效肯定,对于激素禁忌/不耐受或复发难治性患者不失为一种选择。

     

  • [1] KAMISAWA T, EGAWA N, NAKAJIMA H. Autoimmune pancreatitis is a systemic autoimmune disease[J]. Am J Gastroenterol, 2003, 98(12): 2811-2812. DOI: 10.1111/j.1572-0241.2003.08758.x.
    [2] WALLACE ZS, ZHANG Y, PERUGINO CA, et al. Clinical phenotypes of IgG4-related disease: An analysis of two international cross-sectional cohorts[J]. Ann Rheum Dis, 2019, 78(3): 406-412. DOI: 10.1136/annrheumdis-2018-214603.
    [3] LIU Y, XUE M, WANG Z, et al. Salivary gland involvement disparities in clinical characteristics of IgG4-related disease: A retrospective study of 428 patients[J]. Rheumatology (Oxford), 2020, 59(3): 634-640. DOI: 10.1093/rheumatology/kez280.
    [4] LANZILLOTTA M, CAMPOCHIARO C, MANCUSO G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes[J]. Rheumatology (Oxford), 2020, 59(9): 2435-2442. DOI: 10.1093/rheumatology/keaa221.
    [5] DELLA-TORRE E, MANCUSO G, LANZILLOTTA M, et al. Urgent manifestations of immunoglobulin G4-related disease[J]. Scand J Rheumatol, 2021, 50(1): 48-51. DOI: 10.1080/03009742.2020.1771763.
    [6] GHAZALE A, CHARI ST, ZHANG L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy[J]. Gastroenterology, 2008, 134(3): 706-715. DOI: 10.1053/j.gastro.2007.12.009.
    [7] TANAKA A, TAZUMA S, OKAZAKI K, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 920-926.e3. DOI: 10.1016/j.cgh.2016.12.038.
    [8] KAMISAWA T, EGAWA N, NAKAJIMA H, et al. Extrapancreatic lesions in autoimmune pancreatitis[J]. J Clin Gastroenterol, 2005, 39(10): 904-907. DOI: 10.1097/01.mcg.0000180629.77066.6c.
    [9] XU WL, LING YC, WANG ZK, et al. Diagnostic performance of serum IgG4 level for IgG4-related disease: A meta-analysis[J]. Sci Rep, 2016, 6: 32035. DOI: 10.1038/srep32035.
    [10] YAMADA K, YAMAMOTO M, SAEKI T, et al. New clues to the nature of immunoglobulin G4-related disease: A retrospective Japanese multicenter study of baseline clinical features of 334 cases[J]. Arthritis Res Ther, 2017, 19(1): 262. DOI: 10.1186/s13075-017-1467-x.
    [11] BOONSTRA K, CULVER EL, DE BUY WENNIGER LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis[J]. Hepatology, 2014, 59(5): 1954-1963. DOI: 10.1002/hep.26977.
    [12] OSEINI AM, CHAITEERAKIJ R, SHIRE AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma[J]. Hepatology, 2011, 54(3): 940-948. DOI: 10.1002/hep.24487.
    [13] OHARA H, NAKAZAWA T, KAWA S, et al. Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: A Japanese cohort[J]. J Gastroenterol Hepatol, 2013, 28(7): 1247-1251. DOI: 10.1111/jgh.12248.
    [14] KAMISAWA T, SHIMOSEGAWA T, OKAZAKI K, et al. Standard steroid treatment for autoimmune pancreatitis[J]. Gut, 2009, 58(11): 1504-1507. DOI: 10.1136/gut.2008.172908.
    [15] WALLACE ZS, DESHPANDE V, MATTOO H, et al. IgG4-related disease: Clinical and laboratory features in one hundred twenty-five patients[J]. Arthritis Rheumatol, 2015, 67(9): 2466-2475. DOI: 10.1002/art.39205.
    [16] DELLA TORRE E, MATTOO H, MAHAJAN VS, et al. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease[J]. Allergy, 2014, 69(2): 269-272. DOI: 10.1111/all.12320.
    [17] CULVER EL, BARNES E. IgG4-related sclerosing cholangitis[J]. Clin Liver Dis (Hoboken), 2017, 10(1): 9-16. DOI: 10.1002/cld.642.
    [18] YU KH, CHAN TM, TSAI PH, et al. Diagnostic performance of serum IgG4 levels in patients with IgG4-related disease[J]. Medicine (Baltimore), 2015, 94(41): e1707. DOI: 10.1097/MD.0000000000001707.
    [19] DOORENSPLEET ME, HUBERS LM, CULVER EL, et al. Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies[J]. Hepatology, 2016, 64(2): 501-507. DOI: 10.1002/hep.28568.
    [20] LANZILLOTTA M, DELLA-TORRE E, MILANI R, et al. Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease[J]. Clin Exp Rheumatol, 2019, 37 Suppl 118(3): 159-166.
    [21] ITO T, TANAKA T, NAKAMARU K, et al. Interleukin-35 promotes the differentiation of regulatory T cells and suppresses Th2 response in IgG4-related type 1 autoimmune pancreatitis[J]. J Gastroenterol, 2020, 55(8): 789-799. DOI: 10.1007/s00535-020-01689-5.
    [22] ZHANG J, LIAN M, LI B, et al. Interleukin-35 promotes Th9 cell differentiation in IgG4-related disorders: Experimental data and review of the literature[J]. Clin Rev Allergy Immunol, 2021, 60(1): 132-145. DOI: 10.1007/s12016-020-08803-8.
    [23] MINAGA K, WATANABE T, HARA A, et al. Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease[J]. Sci Rep, 2020, 10(1): 14879. DOI: 10.1038/s41598-020-71848-4.
    [24] ZEN Y, LIBERAL R, NAKANUMA Y, et al. Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis[J]. J Hepatol, 2013, 59(5): 1059-1064. DOI: 10.1016/j.jhep.2013.06.016.
    [25] FUJⅡ-LAU LL, LEVY MJ. The role of endoscopic ultrasound in the diagnosis of autoimmune pancreatitis[J]. Gastrointest Endosc Clin N Am, 2017, 27(4): 643-655. DOI: 10.1016/j.giec.2017.06.005.
    [26] TOKALA A, KHALILI K, MENEZES R, et al. Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis[J]. AJR Am J Roentgenol, 2014, 202(3): 536-543. DOI: 10.2214/AJR.12.10360.
    [27] NAKAZAWA T, SHIMIZU S, NAITOH I. IgG4-related sclerosing cholangitis[J]. Semin Liver Dis, 2016, 36(3): 216-228. DOI: 10.1055/s-0036-1584321.
    [28] TABATA T, KAMISAWA T, HARA S, et al. Differentiating immunoglobulin g4-related sclerosing cholangitis from hilar cholangiocarcinoma[J]. Gut Liver, 2013, 7(2): 234-238. DOI: 10.5009/gnl.2013.7.2.234.
    [29] KALAITZAKIS E, LEVY M, KAMISAWA T, et al. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma[J]. Clin Gastroenterol Hepatol, 2011, 9(9): 800-803.e2. DOI: 10.1016/j.cgh.2011.05.019.
    [30] ARORA K, RIVERA M, TING DT, et al. The histological diagnosis of IgG4-related disease on small biopsies: Challenges and pitfalls[J]. Histopathology, 2019, 74(5): 688-698. DOI: 10.1111/his.13787.
    [31] ZEN Y, FUJⅡ T, SATO Y, et al. Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease[J]. Mod Pathol, 2007, 20(8): 884-894. DOI: 10.1038/modpathol.3800836.
    [32] UMEHARA H, OKAZAKI K, KAWA S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD[J]. Mod Rheumatol, 2021, 31(3): 529-533. DOI: 10.1080/14397595.2020.1859710.
    [33] WALLACE ZS, NADEN RP, CHARI S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease[J]. Ann Rheum Dis, 2020, 79(1): 77-87. DOI: 10.1136/annrheumdis-2019-216561.
    [34] KAWA S, KAMISAWA T, NOTOHARA K, et al. Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2018: Revision of Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2011[J]. Pancreas, 2020, 49(1): e13-e14. DOI: 10.1097/MPA.0000000000001443.
    [35] NAKAZAWA T, KAMISAWA T, OKAZAKI K, et al. Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020: (Revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012)[J]. J Hepatobiliary Pancreat Sci, 2021, 28(3): 235-242. DOI: 10.1002/jhbp.913.
    [36] NAKANUMA Y, ISHIZU Y, ZEN Y, et al. Histopathology of IgG4-related autoimmune hepatitis and IgG4-related hepatopathy in igg4-related disease[J]. Semin Liver Dis, 2016, 36(3): 229-241. DOI: 10.1055/s-0036-1584320.
    [37] KURAISHI Y, UEHARA T, WATANABE T, et al. Corticosteroids prevent the progression of autoimmune pancreatitis to chronic pancreatitis[J]. Pancreatology, 2020, 20(6): 1062-1068. DOI: 10.1016/j.pan.2020.07.408.
    [38] BARRESI L, TACELLI M, CRINÒ SF, et al. Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency[J]. United European Gastroenterol J, 2020, 8(6): 705-715. DOI: 10.1177/2050640620924302.
    [39] OKAZAKI K, CHARI ST, FRULLONI L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1): 1-6. DOI: 10.1016/j.pan.2016.12.003.
    [40] KHANDELWAL A, INOUE D, TAKAHASHI N. Autoimmune pancreatitis: An update[J]. Abdom Radiol (NY), 2020, 45(5): 1359-1370. DOI: 10.1007/s00261-019-02275-x.
    [41] HART PA, TOPAZIAN MD, WITZIG TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience[J]. Gut, 2013, 62(11): 1607-1615. DOI: 10.1136/gutjnl-2012-302886.
    [42] DU S, LIU G, CHENG X, et al. Differential diagnosis of immunoglobulin G4-associated cholangitis from cholangiocarcinoma[J]. J Clin Gastroenterol, 2016, 50(6): 501-505. DOI: 10.1097/MCG.0000000000000509.
    [43] LANZILLOTTA M, VINGE-HOLMQUIST O, OVERBEEK KA, et al. PrescrAIP: A Pan-European study on current treatment regimens of auto-immune pancreatitis[J]. Front Med (Lausanne), 2020, 7: 408. DOI: 10.3389/fmed.2020.00408.
    [44] TACELLI M, CELSA C, MAGRO B, et al. Risk factors for rate of relapse and effects of steroid maintenance therapy in patients with autoimmune pancreatitis: Systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2019, 17(6): 1061-1072.e8. DOI: 10.1016/j.cgh.2018.09.051.
    [45] BLAHO M, DÍTĚ P, KUNOVSKÝ L, et al. Autoimmune pancreatitis-An ongoing challenge[J]. Adv Med Sci, 2020, 65(2): 403-408. DOI: 10.1016/j.advms.2020.07.002.
    [46] MASAMUNE A, NISHIMORI I, KIKUTA K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis[J]. Gut, 2017, 66(3): 487-494. DOI: 10.1136/gutjnl-2016-312049.
  • 加载中
计量
  • 文章访问数:  697
  • HTML全文浏览量:  152
  • PDF下载量:  146
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-11
  • 录用日期:  2022-02-13
  • 出版日期:  2022-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回